RSI Overbought Stocks
TERN is RSI overbought, meaning strong buying pressure may lead to a short-term consolidation or pullback.
TERNS PHARMACEUTICALS INC (TERN) Stock Price & Overview
NASDAQ:TERN • US8808811074
Current stock price
52.71 USD
+0.03 (+0.06%)
At close:
52.6 USD
-0.11 (-0.21%)
Pre-Market:
The current stock price of TERN is 52.71 USD. Today TERN is up by 0.06%. In the past month the price increased by 13.43%. In the past year, price increased by 2096.25%.
TERN Key Statistics
52-Week Range2.37 - 53.19
Current TERN stock price positioned within its 52-week range.
1-Month Range45.05 - 53.19
Current TERN stock price positioned within its 1-month range.
- Market Cap
- 6.083B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.03
- Dividend Yield
- N/A
TERN Stock Performance
Today
+0.06%
1 Week
+0.09%
1 Month
+13.43%
3 Months
+44.02%
Longer-term
6 Months +526.75%
1 Year +2,096.25%
2 Years +943.76%
3 Years +303.91%
5 Years +139.59%
10 Years N/A
TERN Stock Chart
TERN Stock Screens
TERN currently appears in the following ChartMill screener lists.
Bull Flag Stocks
TERN is forming a bull flag pattern, suggesting a potential continuation of its upward trend.
Breakout Setups
TERN appears in our Breakout Setups screen. This means the stock shows strong technical strength, a constructive consolidation pattern, and enough volatility to support a potential breakout if price moves above resistance.
TERN Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to TERN. When comparing the yearly performance of all stocks, TERN is one of the better performing stocks in the market, outperforming 99.83% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
TERN Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to TERN. No worries on liquidiy or solvency for TERN as it has an excellent financial health rating, but there are worries on the profitability.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
TERN Earnings
Next Earnings DateMay 6, 2026
Last Earnings DateMar 30, 2026
PeriodQ4 / 2025
EPS Reported-$0.24
Revenue Reported
EPS Surprise 15.44%
Revenue Surprise %
TERN Forecast & Estimates
17 analysts have analysed TERN and the average price target is 51.82 USD. This implies a price decrease of -1.7% is expected in the next year compared to the current price of 52.71.
Analysts
Analysts76.47
Price Target51.82 (-1.69%)
EPS Next Y-15.27%
Revenue Next YearN/A
TERN Groups
Sector & Classification
TERN Financial Highlights
Over the last trailing twelve months TERN reported a non-GAAP Earnings per Share(EPS) of -1.03. The EPS increased by 8.85% compared to the year before.
Income Statements
Revenue(TTM)N/A
Net Income(TTM)-96.21M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -9.39% | ||
| ROE | -9.56% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%0%
Sales Q2Q%N/A
EPS 1Y (TTM)8.85%
Revenue 1Y (TTM)N/A
TERN Ownership
Ownership
Inst Owners107.2%
Shares115.41M
Float112.33M
Ins Owners0.51%
Short Float %12.02%
Short Ratio2.21
TERN Competitors/Peers
The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 25.88 | 855.09B | ||
| JNJ | JOHNSON & JOHNSON | 18.81 | 574.863B | ||
| MRK | MERCK & CO. INC. | 23.15 | 291.495B | ||
| PFE | PFIZER INC | 9.1 | 154.667B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.14 | 118.196B | ||
| ZTS | ZOETIS INC | 17.07 | 50.976B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.42 | 28.093B | ||
| VTRS | VIATRIS INC | 5.56 | 16.139B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.08 | 11.549B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 9.421B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.331B | ||
| CORT | CORCEPT THERAPEUTICS INC | 80.9 | 4.67B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About TERN
Company Profile
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. The company is headquartered in Foster City, California and currently employs 59 full-time employees. The company went IPO on 2021-02-05. The firm is engaged in developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Its product candidates in pipeline includes TERN-701, TERN-601 and TERN-501. TERN-701 is its oral, potent, allosteric BCR-ABL tyrosine kinase inhibitors (TKI) specifically targeting the ABL myristoyl pocket for CML, a form of cancer that begins in the bone marrow and leads to the growth of leukemic cells. TERN-601 is a small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist that is intended to be orally administered for obesity. TERN-501 is a thyroid hormone receptor beta (THR-b) agonist with high metabolic dysfunction-associated steatohepatitis (MASH). The company is also focused on developing the TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity.
Company Info
IPO: 2021-02-05
TERNS PHARMACEUTICALS INC
1065 East Hillsdale Blvd., Suite 100, Suite 100
Foster City CALIFORNIA 94404 US
CEO: Senthil Sundaram
Employees: 59
Phone: 13026587581
TERNS PHARMACEUTICALS INC / TERN FAQ
Can you describe the business of TERNS PHARMACEUTICALS INC?
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. The company is headquartered in Foster City, California and currently employs 59 full-time employees. The company went IPO on 2021-02-05. The firm is engaged in developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Its product candidates in pipeline includes TERN-701, TERN-601 and TERN-501. TERN-701 is its oral, potent, allosteric BCR-ABL tyrosine kinase inhibitors (TKI) specifically targeting the ABL myristoyl pocket for CML, a form of cancer that begins in the bone marrow and leads to the growth of leukemic cells. TERN-601 is a small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist that is intended to be orally administered for obesity. TERN-501 is a thyroid hormone receptor beta (THR-b) agonist with high metabolic dysfunction-associated steatohepatitis (MASH). The company is also focused on developing the TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity.
What is the stock price of TERNS PHARMACEUTICALS INC today?
The current stock price of TERN is 52.71 USD. The price increased by 0.06% in the last trading session.
What is the dividend status of TERNS PHARMACEUTICALS INC?
TERN does not pay a dividend.
How is the ChartMill rating for TERNS PHARMACEUTICALS INC?
TERN has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the market capitalization of TERN stock?
TERNS PHARMACEUTICALS INC (TERN) has a market capitalization of 6.08B USD. This makes TERN a Mid Cap stock.